Business Description
Sangamo Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US8006771062
Total Employee Number:
142Description
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.43 | |||||
Equity-to-Asset | -0.32 | |||||
Debt-to-Equity | -1.02 | |||||
Debt-to-EBITDA | -0.19 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -45.05 | |||||
Beneish M-Score | -3.15 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -42 | |||||
3-Year EBITDA Growth Rate | 32.6 | |||||
3-Year EPS without NRI Growth Rate | 32 | |||||
3-Year FCF Growth Rate | 39.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 88.71 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 11.48 | |||||
9-Day RSI | 20.52 | |||||
14-Day RSI | 27.79 | |||||
3-1 Month Momentum % | -63.18 | |||||
6-1 Month Momentum % | -79.66 | |||||
12-1 Month Momentum % | -87.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.7 | |||||
Quick Ratio | 0.7 | |||||
Cash Ratio | 0.52 | |||||
Days Sales Outstanding | 5.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28.1 | |||||
Shareholder Yield % | -280.76 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -319.25 | |||||
Net Margin % | -356.89 | |||||
EBITDA Margin % | -300.28 | |||||
FCF Margin % | -261.46 | |||||
OCF Margin % | -261.43 | |||||
ROA % | -157.28 | |||||
ROIC % | -185.4 | |||||
3-Year ROIIC % | -31.75 | |||||
ROC (Joel Greenblatt) % | -458.96 | |||||
ROCE % | -369.88 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.62 | |||||
EV-to-EBIT | -0.2 | |||||
EV-to-EBITDA | -0.22 | |||||
EV-to-Forward-EBITDA | -0.26 | |||||
EV-to-Revenue | 0.65 | |||||
EV-to-Forward-Revenue | 0.37 | |||||
EV-to-FCF | -0.25 | |||||
Price-to-GF-Value | 0.37 | |||||
Price-to-Median-PS-Value | 0.06 | |||||
Earnings Yield (Greenblatt) % | -500 | |||||
FCF Yield % | -294.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SGMO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sangamo Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 34.557 | ||
| EPS (TTM) ($) | -0.38 | ||
| Beta | 3.1 | ||
| 3-Year Sharpe Ratio | 0.09 | ||
| 3-Year Sortino Ratio | 0.18 | ||
| Volatility % | 139.36 | ||
| 14-Day RSI | 27.79 | ||
| 14-Day ATR ($) | 0.006194 | ||
| 20-Day SMA ($) | 0.074 | ||
| 12-1 Month Momentum % | -87.67 | ||
| 52-Week Range ($) | 0.0637 - 0.766 | ||
| Shares Outstanding (Mil) | 414.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sangamo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sangamo Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 101 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 100 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 16:30 | In 17 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 16 days | ||
| General meeting for 2026 | 2026-07-31 09:00 | In 3 days | ||
| First quarter earnings conference call for 2026 | 2026-05-14 16:30 | 0.14 (-6.44%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.14 (-6.44%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 16:30 | 0.32 (-7.07%) | ||
| Annual report for 2025 | 2026-03-30 | 0.32 (-7.07%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 0.32 (-7.07%) |
Show
Entries
Sangamo Therapeutics Inc Frequently Asked Questions
What is Sangamo Therapeutics Inc(SGMO)'s stock price today?
The current price of SGMO is $0.07. The 52 week high of SGMO is $0.77 and 52 week low is $0.06.
When is next earnings date of Sangamo Therapeutics Inc(SGMO)?
The next earnings date of Sangamo Therapeutics Inc(SGMO) is 2026-08-14 Est..
Does Sangamo Therapeutics Inc(SGMO) pay dividends? If so, how much?
Sangamo Therapeutics Inc(SGMO) does not pay dividend.
Guru Commentaries on OTCPK:SGMO
No articles.
Press Release
Articles on Sangamo Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers